- "We believe that the ASCEND trial of pirfenidone for idiopathic pulmonary fibrosis will be successful when the data is top lined Q2 2014," Summer Street's Bart Classen says, in a bullish note on shares of InterMune (ITMN +0.3%) which he says could rise another 20% in Q1.
- "The trial is similar to three previous Phase 3 trials but is only 52 weeks in duration," Classen notes, before adding that "all previous trials were statistically significant in the 48-52 week range."
- As an aside, Summer Street doesn't think Boehringer Ingelheim’s nintedanib will succeed in IPF.
Summer Street sees further upside for InterMune
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs